Automating Dermatology Prior Authorizations for Magellan Healthcare

Klivira streamlines prior authorizations for dermatology magellan healthcare services, addressing the unique challenges of biologics, specialty topicals, and Mohs surgery.

Revenue cycle directors and prior authorization coordinators face significant administrative burdens navigating specific payer policies. For dermatology practices managing patients covered by Magellan Healthcare, efficient prior authorization is critical to ensure timely access to high-cost biologics and specialized procedures. Klivira's platform automates this complex workflow, integrating directly with your EMR to align with Magellan's utilization management requirements.

Navigating Magellan Healthcare's Utilization Management for Dermatology

Magellan Healthcare, a Centene company, administers utilization management for a broad range of medical and pharmacy benefits. For dermatology, this translates to specific prior authorization protocols for high-cost medications and certain surgical procedures. Understanding Magellan's criteria is essential for smooth approvals and minimizing administrative overhead for conditions like psoriasis, atopic dermatitis, and hidradenitis suppurativa.

Key Dermatology Services Requiring Prior Authorization with Magellan

Biologics for psoriasis and psoriatic arthritis (e.g., Dupixent, Cosentyx, Tremfya, Skyrizi, Humira, Enbrel, Taltz, Siliq, Bimzelx, Ilumya, Otezla, Sotyktu, JAK inhibitors)
Biologics for atopic dermatitis (e.g., Dupixent, Adbry, Ebglyss, oral JAK inhibitors like Rinvoq, Cibinqo)
Biologics for hidradenitis suppurativa (e.g., Humira, Cosentyx)
Mohs micrographic surgery, particularly for non-melanoma skin cancers in cosmetically sensitive areas
Advanced skin cancer treatments, including immunotherapies (Keytruda, Opdivo, Yervoy) and targeted therapies
Certain phototherapy modalities, especially self-administered home phototherapy

Magellan-Specific Documentation for Dermatology PA

Magellan Healthcare's prior authorization reviews for dermatology services are informed by clinical guidelines such as those from the AAD and NCCN. Submitting complete and accurate documentation is paramount. This includes detailed clinical notes, trial of prior therapies, and disease severity scores relevant to the specific condition and requested treatment.

Common Documentation Requirements for Magellan Dermatology PAs

Diagnosis confirmation (e.g., PASI/BSA for psoriasis, EASI/SCORAD for atopic dermatitis)
Documentation of prior topical, phototherapy, or conventional systemic therapy trials
Evidence of pre-biologic screenings (e.g., TB, hepatitis)
Site, tumor type, and AAD Appropriate Use Criteria conformance for Mohs surgery
Age-appropriate criteria for specific biologic indications
Distinction between clinic-administered and home phototherapy

Reducing Denials for Dermatology PAs with Magellan Healthcare

Common denial reasons from Magellan Healthcare for dermatology prior authorizations often stem from incomplete documentation of step therapy compliance, missing severity scores, or non-adherence to Mohs Appropriate Use Criteria. Klivira's platform helps proactively identify and address these gaps before submission, aligning with Magellan's specific policy requirements.

Klivira's Solution for Dermatology Prior Authorizations with Magellan

Klivira automates the complex dermatology magellan healthcare prior authorization process. Our platform integrates with your EMR, leveraging AAD-guideline-aware step-therapy logic for biologics, AUC validation for Mohs surgery, and smart workflows for periodic re-authorizations. We streamline the submission process through X12 278 transactions and direct payer portal connectivity, reducing manual effort and accelerating approvals.

Frequently asked questions

Which dermatology conditions are most frequently subject to prior authorization by Magellan Healthcare?

Magellan Healthcare commonly requires prior authorization for chronic conditions treated with high-cost biologics, such as psoriasis, psoriatic arthritis, atopic dermatitis, and hidradenitis suppurativa. Additionally, Mohs micrographic surgery, particularly for non-melanoma skin cancers in sensitive areas, is a frequent PA trigger.

What are the typical documentation challenges for dermatology magellan healthcare prior authorizations?

Key challenges include demonstrating compliance with step therapy protocols (e.g., trials of topicals or conventional systemics), documenting disease severity using standardized scores (PASI, EASI, BSA), and providing evidence of pre-biologic screenings like TB and hepatitis. For Mohs surgery, adherence to AAD Appropriate Use Criteria is critical.

How does Klivira address periodic re-authorization requirements for chronic dermatology treatments with Magellan?

Klivira's platform incorporates automated workflows for periodic re-authorization, a common requirement for chronic biologic treatments in dermatology. It tracks re-authorization cycles, prompts for necessary updated documentation, and facilitates timely resubmission to Magellan Healthcare to ensure continuity of care.

Can Klivira help differentiate between medical and pharmacy benefit routing for dermatology drugs with Magellan?

Yes, Klivira's system is designed to assist with medical-vs-pharmacy benefit routing for dermatology medications, especially for biologics that may be self-injected at home or administered in a clinic. This ensures the correct prior authorization channel is used, whether through X12 278 for medical benefits or ePA/NCPDP SCRIPT for pharmacy benefits.

What clinical guidelines does Magellan Healthcare typically reference for dermatology prior authorizations?

Magellan Healthcare's utilization management policies for dermatology are commonly informed by established clinical frameworks such as the American Academy of Dermatology (AAD) Clinical Guidelines for conditions like psoriasis and atopic dermatitis, and the National Comprehensive Cancer Network (NCCN) Guidelines for advanced skin cancer treatments.